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Conclusion: The use of drug-eluting stents in patient with DM was safe with low acute
complication. Patients treated with BES and EES showed lesser rate of restenosis
compared with ECS.
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Background: The RESOLUTE Clinical Program comprises 5 trials worldwide
evaluating the Resolute zotarolimus-eluting stent (R-ZES), which were prospectively
designed with similar methods including: data collection forms, adverse event
definitions and adjudication procedures, statistical programming algorithms and data
sets to allow pooling. The R-ZES is a contemporary drug-eluting stent composed of a
thin-strut cobalt alloy BMS and a proprietary polymer with hydrophilic properties for
biocompatibility and hydrophobic properties for uniform prolonged drug release (85%
delivered by 60 days; remaining up to 180 days). Extended elution may better balance
arterial healing, and any associated sustained proliferative stimuli, in high-risk patients
such as those with diabetes mellitus (DM). We will present pooled clinical outcomes
at 1-year for patients with DM treated with the R-ZES.
Methods: To date, 5130 patients have been enrolled in 247 centers in 5 R-ZES Trials
(Resolute First-In-Man [139], Resolute All Comers [1140], Resolute International
[2349], Resolute United States [1402], Resolute Japan [100]). We compared baseline
characteristics and clinical outcomes at 1 year for 1535 patients with DM vs those
without DM, as well as by insulin requirements.
Results: Of 1535 patients with DM, 455 (29.6%) were insulin treated. At baseline DM
patients were older, more were female, with hyperlipidemia, hypertension, previous
coronary artery bypass grafting, and moderate/severe calcification. At 1 year, the rates
of target lesion failure (cardiac death, target-vessel MI, clinically-driven TLR) were
7.8% for DM vs. 6.1% for non-DM (p=0.03); patient-oriented composite (all death,
all MI, all revascularization) (15.6% vs. 12.1%, p < 0.001); cardiac death and target-
vessel-related MI (4.7% vs. 3.6%, p = 0.08); clinically-driven TLR (4.0%vs. 2.9%,
p=0.06); and ARC definite and probable ST (1.1% vs. 0.7%, p=0.17). We will also
report outcomes by insulin requirements.
Conclusion: In this large diverse patient cohort with DM, the R-ZES had low event
rates despite the high-risk nature of this population.
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Background: Diabetes is associated with an increased risk of major adverse cardiac
events (MACE) following percutaneous coronary intervention. In this substudy of the
SORT OUT IV trial, we compared the clinical outcome among patient with and without
diabetes mellitus treated with everolimus-eluting (EES) or sirolimus-eluting (SES).
Methods: Of 2,774 patients, 390 (14.1%) patients had diabetes and were treated with
EES (n=1,390, diabetes: n = 194) or SES (n = 1,384, diabetics: n=196). Randomization
was stratified by presence/absence of diabetes. The primary endpoint was MACE,
defined as a composite of cardiac death, myocardial infarction (MI), definite stent
thrombosis or target vessel revascularization within 18 months.
Results: At 18-month, MACE were higher among diabetic patients (diabetic patients:
13.1% vs. non-diabetic patients: 6.4%; Hazard ratio (HR) 95% confidence interval
2.08 (1.51 - 2.86). At 18-month MACE was 10.3% in the EES- and 15.8% in the SES-
treated diabetic patients (HR 0.63 95% CI 0.36-1.11) and 6.6% in the EES- and 6.3 in
the SES-treated patients without diabetes (HR 1.06 95% CI 0.77-1.46). In diabetic
patients cardiac death 3.1% in EES- and 4.6% in SES-treated patients (HR 0.67 95%
CI 0.24-1.89), MI 0.5% in EES- and 3.6% in SES-treated patients (HR 0.14 95% CI
0.02-1.16) and clinically driven target lesion revascularization 3.1% in EES- and 7.7%
in SES-treated patients (HR 0.40 95% CI 0.15-1.02) did not differ between EES and
SES treated patients. Definite stent thrombosis was not seen in diabetic patients treated
with EES compared to 4 patients treated with SES.
Conclusion: EES showed a non-significant reduced risk of MACE compared to SES
in patients with diabetes mellitus.
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Background: Critical Limb Ischemia (CLI) with or without lower extremity
amputation (LEA) is reported as an independent predictor of cardiac mortality in
diabetic patients and these deaths are related to the high prevalence of CAD in these
subjects. The aim of our study was to investigate the impact on long-term cardiac
mortality of the association of CAD with CLI in diabetic patients and the potential
effect of coronary and limb revascularization
Methods: The study was designed as a prospective single centre registry which
enrolled and followed for 4 years 764 consecutive diabetic patients undergoing
percutaneous coronary intervention (PCI), between July 2002 and May 2007. The
development of CLI was diagnosed by a dedicated diabetic foot-clinic specialist. All
patients with CLI underwent peripheral revascularization of the culprit limb. Cardiac
mortality was the primary endpoint of the study.
Results: Among the 764 PCI patients, 111 (14%) developed CLI during follow-up
(PCI+CLI group) and were treated with peripheral intervention in 145 limbs with
procedural success in 140 (96%). PCI+CLI patients had lower left ventricle ejection
fraction (LVEF) (51±11% vs 53±10%, p=0.008) higher renal failure (25% vs 12%,
p=0.005), dialysis (7% vs 0.3%, p<0.0001) and diabetes duration (13.8 vs 11.7 years,
p=0.02) compared to PCI-only patients. Coronary intervention procedural
characteristics did not differ among PCI-only and PCI-CLI patients. At 4-year follow
up, cardiac mortality occurred in 10(9%) PCI-CLI vs 39(6%) PCI-only patients
(p=0.2). Major amputation occurred in 6(5%) patients. Cox regression analysis showed
age (OR 1.06, 95%CI 1.02-1.09), dialysis (OR 8.02, 95%CI 4.02-18.3) and LVEF<30%
(OR 9.40, 95%CI 4.20-20.61) to be the independent predictors of cardiac mortality
which was not influenced by the development of CLI (OR 0.93, 95%CI 0.42-2.06).
Conclusion: In diabetic patients treated with percutaneous coronary revascularization,
the development of CLI, treated with peripheral intervention, seems not to impact
cardiac mortality long terms.
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Background: In acute myocardial infarction (AMI) patients treated with percutaneous
coronary intervention (PCI), presence of diabetes mellitus (DM) imparts worse
cardiovascular outcomes. In this study, we evaluated the influence of glycemic control
on clinical outcomes in DM patients with AMI after successful PCI.
Methods: We examined 231 consecutive DM patients with AMI who underwent
successful primary PCI and had evaluation of glycosylated hemoglobin (HbA1c) from
30 days before to 90 days after AMI. Patients were categorized in two groups,
controlled DM with HbA1c ≤ 7.0 (N=83, 36%) and uncontrolled DM with HbA1c >
7.0 (N = 148, 64%). We assessed 12-month cardiovascular outcomes in study groups.
Results: Uncontrolled diabetics were younger, tended to be less hypertensive, and had
higher baseline glomerular filtration rate and final vessel diameter compared to
controlled diabetics. Uncontrolled DM patients had similar MACE [composite of all-
cause death, myocardial infarction (MI), target vessel revascularization (TVR), and
stent thrombosis (ST); (20 vs. 30%, log rank p=0.54, figure], death (8.8 vs. 12%,
p=0.40), MI (8.8 vs. 9.6%, p=0.76), TVR (9.5 vs. 8.4%, p=0.95) and ST (3.4 vs. 4.8%,
p=0.54) as the controlled diabetics. In Cox regression analysis, after adjustment for
baseline differences, glycemic control had no independent influence on study
outcomes.
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Figure: Cumulative incidence of major adverse cardiovascular events in the two
study groups.
Conclusion: Glycemic control, determined by HbA1c, does not seem to influence 12-
month cardiovascular outcomes in DM with AMI after successful PCI.
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Background: We prospectively investigated the effects of pioglitazone in reducing
MACEs after zotarolimus-eluting stent (ZES) implantation in type 2 diabetic patients
with significant coronary artery narrowing during the 3-year follow-up.
Methods: Type 2 diabetic patients with coronary artery diseases were randomly
assigned to pioglitazone (n=91) or placebo (n=114) after ZES implantation. Primary
endpoint was to compare MACEs such as non-fatal myocardial infarction, death,
stroke, and target lesion revascularization (TLR) between the 2 groups during the 3-
year follow-up. Secondary endpoints were to compare rates of new-onset heart failure,
fracture, and non-TLR target vessel revascularization (TVR) between the 2 groups.
Results: MACEs were significantly higher in the placebo group than the pioglitazone
group during the follow-up [hazard ratio 2.326 (95% CI 1.167-4.638), p=0.016] (Figure
1). Rates of non-fatal myocardial infarction [odds ratio (OR) 1.011 (95% CI 0.989-
1.033)], death [OR 0.974 (95% CI 0.945-1.004)], and stroke [OR 2.537 (95% CI
0.227-28.456)] showed no significant differences between the 2 groups; however, TLR
[OR 0.322 (95% CI 0.144-0.721)] was significantly lower in the pioglitazone group
than the placebo group. Rates of new-onset heart failure [OR 2.222 (95% CI 0.776-
6.365)], fracture [OR 1.636 (95% CI 0.618-4.331)] and non-TLR TVR [OR 1.261
(95% CI 0.248-6.403)] revealed no significant differences between the 2 groups.
Conclusion: Rates of MACEs were significantly lower in the pioglitazone group when
compared with the placebo group, mainly due to the lower rate of TLR during the 3-
year follow-up.
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Background: International guidelines recommend the use of drug eluting stents in all
diabetics, regardless of other restenosis risk factors. However, bare metal stents (BMS)
are generally a safe and effective treatment option for low risk of restenosis lesions
(LR lesions). Hence, we analyzed results of diabetics undergoing percutaneous
coronary intervention (PCI) for LR lesions treated with BMS.
Methods: The study population is a single center prospective cohort that underwent
non-urgent PCI between 2003 and 2007. LR lesions were defined as a reference vessel
diameter≥3.0 mm and lesion length≤15 mm. All cardiac events were collected up to 1
year of follow-up. Patients treated with BMS were stratified as no(noDM), non-insulin
requiring (NIRDM) and insulin requiring (IRDM) diabetics. Cumulative event rates
were estimated with the Kaplan-Meier method and compared with a log-rank test.
Results: We included a total of 1951 patients; 1596 noDM, 231 NIRDM, and 124
IRDM. Target lesion revascularization (TLR) rates in non-DM versus NIRDM were
similar (6.3% vs. 5.6%; p=0.68), while TLR in IRDM was higher (6.3% vs. 14.4%;
p=0.03) (Figure). The composite of cardiac death, myocardial infarction and target
vessel revascularization was not significantly different in non-DM versus NIRDM
(9.5% vs. 13.4%; p=0.07), though in IRDM it was higher (9.5% vs. 17.7; P<0.01).
Conclusion: The results implicate that BMS placement may be considered in patients
with NIRDM and LR lesions. Further work is required to define treatment strategies
and, more importantly, improve the outcomes in diabetics.
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Background: The incidence of contrast induced acute kidney injury (CI-AKI)
following coronary angiography/PCI in patients with DM may be up to 30% and is
associated with increased long term morbidity/mortality. Patients with CKD are
excluded from the majority of cardiology trials and are at high risk for development
of CI-AKI. We aimed to identify whether a panel of novel biomarkers could predict
CI-AKI early post procedure allowing earlier identification of affected patients. We
also assessed severity of CAD and whether this influenced the development of CI-
AKI.
Methods: We recruited 208 consecutive patients undergoing elective/urgent coronary
angiography/PCI with known DM and CKD (eGFR <60ml/min). CI-AKI was defined
as a rise in creatinine at day 3 of >25% from baseline or an absolute rise of 44.5μmol/l.
Severity of CAD was assessed by the SYNTAX Score and risk of CI-AKI using the
Mehran score. We evaluated serum and urine NGAL and Il-18 and albuminuria for
additional information about CI-AKI risk. NAC and iv hydration were given to all
patients with eGFR <50 ml/min in accordance with local guidelines.
Results: 116 patients underwent coronary angiography and 92 PCI. 39 patients (18.8%)
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